α-Synuclein Aggregation in Treatment of Parkinson's Disease

Parkinson’s disease, the second most common neurodegenerative disorder worldwide, is characterized by the accumulation of protein deposits in the dopaminergic neurons. These deposits are primarily composed of aggregated forms of α-Synuclein (α-Syn). PD is a complex pathology initially associated with motor deficiencies, as a result of an acute neuronal loss in substantia nigra pars compacta (SNc), with a significant dopaminergic (DA) impairment.

IJMS, Free Full-Text

Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease

α-Synuclein Aggregation in Treatment of Parkinson's Disease

Tissue transglutaminase-induced aggregation of α-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies

ISIS Studying the influence of salts on α-synuclein aggregation, a hallmark of Parkinson's disease

α‐Synuclein Radiotracer Development and In Vivo Imaging: Recent Advancements and New Perspectives - Alzghool - 2022 - Movement Disorders - Wiley Online Library

Aggregated α-Synuclein Mediates Dopaminergic Neurotoxicity In Vivo

Intra-mitochondrial protein degradation alleviates alpha-synuclein seeding and Abeta 42 aggregation

IJMS, Free Full-Text